S. 2274, The Dextromethorphan Abuse Reduction Act of 2007

• This item is from the 110th Congress (2007-2008) and is no longer current. Comments, voting, and wiki editing have been disabled, and the cost/savings estimate has been frozen.

Version saved on March 14, 2008, 04:11:25, by webmaster:

S. 2274 would amend the Controlled Substances Act to prevent the abuse of dextromethorphan.

Detailed Summary

Dextromethorphan Abuse Reduction Act of 2007 - Amends the Controlled Substances Act to: (1) set forth definitions relating to dextromethorphan in unfinished or finished dosage form; (2) classify unfinished dextromethorphan as a Schedule V controlled substance; and (3) impose civil penalties for sales of products containing dextromethorphan to individuals under the age of 18.

Expresses the sense of the Senate that: (1) manufacturers of products containing dextromethorphan should provide warnings about the dangers of dextromethorphan misuse; and (2) retailers should impose safeguards to protect against the theft of products containing dextromethorphan.

Directs the Director of National Drug Control Policy to make grants to the Partnership for a Drug-Free America and the Community Anti-Drug Coalition of America for education programs to prevent the abuse of prescription and nonprescription drugs (including dextromethorphan).

Authorizes the Administrator of the Substance Abuse and Mental Health Services Administration to make grants to certain communities to implement comprehensive community-wide strategies for addressing abuse of prescription and nonprescription drugs.

Status of the Legislation

Latest Major Action: 3/12/2008: Senate committee/subcommittee actions. Status: Committee on the Judiciary Senate Subcommittee on Crime and Drugs. Hearings held.

Points in Favor

(Log in to edit the wiki and be the first to show why the bill should pass!)

Points Against

(Log in to edit the wiki and be the first to show why the bill should not pass!)

« Return to Revision History.